Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive the group has recently enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-083 drug. Zarrabian says the recurrent arm of the study addresses patients suffering from GBM who have been pre-treated with the drug temozolomide (TMZ) prior to disease recurrence. The trial is designed to treat up to 83 patients to determine whether treatment with VAL-083 improves overall survival.
Kintara achieves 'major milestone' by enrolling last patient in Phase 2 trial to treat brain cancer
Quick facts: Kintara Therapeutics
Price: 0.88 USD
Market Cap: $28.7 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE